Rapid Automated Immunoassay for HTLV I/II Antibodies Now Available
|
By LabMedica International staff writers Posted on 05 Aug 2015 |
|
Image: The Elecsys benchtop analyzer was designed for small to medium workloads (Photo courtesy of Roche).
An automated immunoassay for the detection of antibodies against human T-lymphotropic virus I or II (HTLV-I/II) in donated blood and routine diagnostic samples and is now available for use by blood centers and clinical laboratories.
The Roche (Basel, Switzerland) HTLV-I/II immunoassay was designed for use on the Elecsys benchtop analyzer. This IVD instrument is powered by enhanced chemiluminescence (ECL) technology, which provides precise and reliable patient results that contribute to better patient care.
The Elecys instrument uses two electrochemically active substances, a ruthenium complex and tripropylamine (TPA). These reagents are involved in the reaction that leads to the emission of light. Ruthenium and TPA are non-isotopic and highly stable at base state. Only when voltage is applied and the labeled compound is repeatedly excited do the reactants begin emitting photons. To start the reaction, voltage is applied between the working and counter electrode, and an electrical field is created, ensuring a precisely controlled and timed reaction.
The operation is performed on a solution containing sample and reagents that are aspirated into the measuring cell. A magnetic field is applied, and the paramagnetic beads (coated with antigen/antibody complexes bound by streptavidin-biotin) are bound to the surface of the measuring cell. ProCell solution is introduced in order to separate the bound immunoassay complexes from the free remaining particles and to provide TPA, which is essential for the ECL-reaction. The test procedure requires about 18 minutes to run a single test.
“Globally there are around 20 million people infected with HTLV-I/II, many of whom are unknown carriers. If the virus is undetected in donors, the risk of spreading the infection increases,” said Roland Diggelmann, COO of the Roche Diagnostics Division. “Roche is uniquely positioned to help blood centers improve their testing efficiency, based on our broad assay portfolio and integrated molecular and serology laboratory solutions.”
Related Links:
Roche
.jpg)
The Roche (Basel, Switzerland) HTLV-I/II immunoassay was designed for use on the Elecsys benchtop analyzer. This IVD instrument is powered by enhanced chemiluminescence (ECL) technology, which provides precise and reliable patient results that contribute to better patient care.
The Elecys instrument uses two electrochemically active substances, a ruthenium complex and tripropylamine (TPA). These reagents are involved in the reaction that leads to the emission of light. Ruthenium and TPA are non-isotopic and highly stable at base state. Only when voltage is applied and the labeled compound is repeatedly excited do the reactants begin emitting photons. To start the reaction, voltage is applied between the working and counter electrode, and an electrical field is created, ensuring a precisely controlled and timed reaction.
The operation is performed on a solution containing sample and reagents that are aspirated into the measuring cell. A magnetic field is applied, and the paramagnetic beads (coated with antigen/antibody complexes bound by streptavidin-biotin) are bound to the surface of the measuring cell. ProCell solution is introduced in order to separate the bound immunoassay complexes from the free remaining particles and to provide TPA, which is essential for the ECL-reaction. The test procedure requires about 18 minutes to run a single test.
“Globally there are around 20 million people infected with HTLV-I/II, many of whom are unknown carriers. If the virus is undetected in donors, the risk of spreading the infection increases,” said Roland Diggelmann, COO of the Roche Diagnostics Division. “Roche is uniquely positioned to help blood centers improve their testing efficiency, based on our broad assay portfolio and integrated molecular and serology laboratory solutions.”
Related Links:
Roche
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Latest Hematology News
- Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
- New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
- Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
- New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
- New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
- New Automated Hemostasis Systems Become Available Across US Laboratories
- Updated Ferritin Thresholds Improve Detection of Iron Deficiency
- Variation in AML Residual Disease Testing Prompts Push for Standardization
- Hidden Molecular Mechanism Behind HIT Blood-Clotting Disorder Revealed
- Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
- Biomarker-Guided Framework Aims to Guide Mantle Cell Lymphoma Therapy
- New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
- Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
- Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
- Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Channels
Clinical Chemistry
view channel
Blood Proteins Linked to Mortality Risk and Biological Aging Across Organ Systems
Older adults of the same chronological age can differ markedly in health, chronic disease burden, and resilience. Biological age aims to capture these differences by reflecting how rapidly the body and... Read more
Two-Step Blood Test Improves Specificity for Alzheimer’s Diagnosis
Early Alzheimer’s disease can be difficult to identify before more severe cognitive symptoms emerge. Blood tests measuring phosphorylated tau protein p-tau217 may help detect disease-related changes, but... Read more
Molecular Diagnostics
view channel
Tumor and Immune Biomarkers Linked to Treatment Response in T-Cell Lymphoma
T-follicular helper cell lymphoma (TFHL) is a subtype of peripheral T-cell lymphoma associated with poor prognosis and limited treatment options after relapse. Its molecular abnormalities include frequent... Read more
Blood MRD Testing Aids Risk Analysis in Bladder and Other Cancers
Natera (Austin, TX, USA) presented findings from 25 abstracts, including nine oral presentations, at the ESMO Congress 2026 in Madrid. The research examined circulating tumor DNA (ctDNA) testing for molecular... Read more
Hematology
view channel
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more
Immunology
view channel
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read more
Immune and Inflammatory Markers May Help Assess CAR T-Cell Complication Risk
Cytokine release syndrome (CRS) can occur after chimeric antigen receptor (CAR) T-cell therapy in patients with autoimmune disease. Identifying which patients are more likely to develop this complication... Read more
Microbiology
view channel
Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Pathology
view channel
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
Mesothelioma is a rare, deadly cancer that forms in the tissue lining many internal organs. Most patients are diagnosed late, with median overall survival reported at 12 to 18 months. Differential diagnosis... Read more
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreIndustry
view channel
CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries
Clinical laboratories using sequencing in regulated diagnostic workflows need systems that support clearly defined processes and documentation. In Europe, meeting applicable EU IVDR requirements also means... Read more
